Subjective evaluation of gray-scale and Doppler ultrasound findings (i.e., pattern recognition) by an experienced examiner and preoperative serum levels of CA-125 can both discriminate benign from malignant adnexal (i.e., ovarian, paraovarian, or tubal) masses. We compared the diagnostic performance of these methods in a large multicenter study.
Preoperative disease classifi cation for patients with ovarian masses, in particular discrimination between benign and malignant ovarian tumors, is important for optimal patient management. At present it is not clear whether subjective evaluation of an ultrasound image (i.e., pattern recognition) of an adnexal (i.e., ovarian, paraovarian, or tubal) mass or determination of serum CA-125 levels is the best method to distinguish benign from malignant tumors.
CA-125 is a glycoprotein that is assessed by the monoclonal antibody OC 125. An elevated CA-125 serum level of at least 30 U/mL is often considered to indicate the presence of malignancy ( 1 -3 ) , although other CA-125 cutoff values have also been used (e.g., ≥ 35 U/mL in postmenopausal women and ≥ 65 U/mL in premenopausal women) ( 4 -8 ) . Serum CA-125 levels can also be misleading -false-positive results can be obtained in women who have conditions that affect the peritoneal surface, such as endometriosis ( 9 ) , and false-negative results can be obtained in women who have early-stage invasive disease and borderline ovarian tumors ( 9 -12 ) . Notwithstanding these limitations, measurement of CA-125 serum levels has become standard practice for the preoperative evaluation of ovarian masses. Although CA-125 serum levels can discriminate between benign and malignant adnexal masses, little is known about the ability of CA-125 serum levels to discriminate among histologic subgroups of adnexal lesions ( 9 , 13 -15 ) . Moreover, most published studies on histologic subgroups are based on CA-125 data from small numbers of patients that were analyzed as categorical data by use of a defi ned cutoff value, rather than as a continuous data.
Gray-scale and Doppler ultrasound examination of adnexal masses can also be used to discriminate between benign and malignant tumors ( 4 , 16 -21 ) . An experienced examiner's subjective evaluation of gray-scale ultrasound morphology and color Doppler fi ndings of an ovarian mass (i.e., pattern recognition) has been shown to be highly accurate and to be better than mathematical models at predicting whether adnexal tumors are malignant or benign ( 20 , 22 ). An experienced ultrasound examiner can also frequently identify the specifi c histologic type of an adnexal mass ( 21 , 23 -26 ) .
To our knowledge, there are no published reports comparing the diagnostic performance of CA-125 with that of ultrasound pattern recognition. The aim of this study was to compare the diagnostic performance of pattern recognition by an experienced examiner with that of preoperative levels of serum CA-125 with regard to discrimination between benign and malignant adnexal masses and also to discriminate among subgroups of adnexal masses.
Patients and Methods

Study Participants
We used information from the International Ovarian Tumor Analysis (IOTA) database. The IOTA study was a multicenter study that included nine European ultrasound centers. It was approved by the local ethics committees and has been described in detail previously ( 27 ) . Oral informed consent was obtained. Women were recruited to the study between June 1, 1999, and June 30, 2002 . Women with at least one persistent adnexal mass underwent gray-scale and color Doppler ultrasonography that was performed by experienced ultrasound examiners who used a standardized examination technique and standardized terms and definitions ( 28 ) . All women received a transvaginal scan; transabdominal sonography was also performed when large masses could not be fully visualized by use of a transvaginal probe. Whenever possible, ultrasound examiners provided a specific histologic diagnosis (e.g., endometrioma, dermoid cyst, or hydrosalpinx [i.e., fluid collection in the Fallopian tube]) by use of pattern recognition data ( 24 ) . The ultrasound examiner had no knowledge of the CA-125 serum levels when suggesting a diagnosis.
In this analysis, a woman was considered to be postmenopausal if she reported no menstruation for at least 1 year after the age of 40 years, provided that the amenorrhea was not explained by medication or disease. Women who were aged 50 years or older and had undergone a hysterectomy, so that the time of menopause could not be determined, were also defi ned as postmenopausal. Women with menstrual periods during the year before the examination and women who were younger than 50 years and had undergone a hysterectomy without bilateral oophorectomy were defi ned as premenopausal.
CA-125 Assay
Centers were encouraged to measure the level of serum CA-125 in peripheral blood from all patients, but the availability of this measurement was not an essential requirement for participation in the study. Second-generation immunoradiometric assay kits for CA-125 (i.e., CA-125 II) ( 29 ) were obtained from five companies (Centocor, Malvern, PA; Cis-Bio, Gif-sur-Yvette, France; Abbott Axsym system, REF 3B41-22, Abbott Laboratories Diagnostic Division, Abbott Park, IL; Immuno-l-analyser, Bayer Diagnostics, Tarrytown, NY; or Vidas, bioMérieux, Marcy l'Etoile, France). All kits used the OC 125 antibody.
Histology
The histology of surgically removed ovarian tissues was the final endpoint of the study. Tumors were classified according to the criteria recommended by the International Federation of Gynecology and Obstetrics ( 30 ) . When the tumor was malignant, the surgical stage was recorded. Histologic diagnoses were grouped into 15 categories -11 of which were benign and four of which were malignant. For subjective assessment of the mass on the basis of ultrasound findings, in addition to these 15 categories, a 16th category was added -i.e., "don't know." The four specific diagnoses of malignancy were primary invasive ovarian cancer, metastasis, borderline tumor, and rare type of malignancy (e.g., granulosa
CONTEXT AND CAVEATS
Prior knowledge
Subjective evaluation of gray-scale and Doppler ultrasound findings (i.e., pattern recognition) by an experienced examiner and preoperative serum levels of CA-125 can both discriminate benign from malignant adnexal (i.e., ovarian, paraovarian, or tubal) masses.
Study design
Multicenter prospective study of 1066 women with a persistent adnexal mass that compared the abilities of pattern recognition and of CA-125 serum levels to classify masses as benign or malignant and to classify them further by histologic subtype. After its resection, each mass was examined histologically.
Contribution
Pattern recognition by an experienced examiner was superior to serum CA-125 for discrimination between benign and malignant adnexal masses and correctly classified more than half of the masses by subtype.
Implications
Measurement of CA-125 is not as helpful as pattern recognition by an experienced examiner for the correct classification of adnexal masses. Because the accuracy of pattern recognition depends on the level of experience of the examiner, more effort should be expended to educate and train ultrasound examiners.
Limitations
CA-125 serum levels were not available for 24% of patients, most of whom had benign masses by pattern recognition with a high degree of confidence. These results reveal a bias whereby serum CA-125 was more likely to be measured in women with masses that were suspected of being malignant. cell tumor or dysgerminoma). The 11 benign diagnoses were endometrioma, teratoma or dermoid cyst, simple cyst, functional cyst, hydrosalpinx, peritoneal pseudocyst, abscess, fibroma, serous cystadenoma, mucinous cystadenoma, and rare type of benign tumor (e.g., Brenner tumor).
Statistical Analysis
Because CA-125 is a continuous variable and pattern recognition is binary, we did not perform a power calculation. Instead, we aimed for a large database to produce reliable estimates of statistical quantities and their confidence intervals (CIs). A large database also allowed us to investigate CA-125 levels for all 15 diagnostic subgroups. All statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, NC). The 95% confi dence interval for a single proportion was computed by use of Wilson's score confi dence interval method with continuity correction ( 31 ) . For a difference between two proportions, the 95% confi dence interval was computed with method 10 as described by Newcombe for paired ( 32 ) and unpaired ( 33 ) proportions, respectively. The methods used for differences between proportions are based on Wilson's score interval. In addition, we report paired P values from McNemar's test and unpaired P values from Fisher's exact test, where appropriate.
The percentages of correctly classifi ed benign and malignant tumors represent the specifi city and the sensitivity, respectively. The percentage of correctly classifi ed tumors in general represents the accuracy, which is infl uenced by the prevalence of malignant tumors. The positive likelihood ratio (LR+) is computed as the sensitivity divided by 100 minus the specifi city. The negative likelihood ratio (LR -) is computed as 100 minus the sensitivity divided by the specifi city.
One test (e.g., pattern recognition or serum CA-125) was considered to be superior to another test if it was associated with a higher sensitivity at the same or similar specifi city or with a higher specifi city at the same or similar sensitivity. If a test had a sensitivity for malignancy of less than 50%, that test was considered to be clinically useless.
To determine the difference in CA-125 serum levels between any two diagnostic groups, the index for effect size (with its 95% Table 1 . Demographic background data, histologic diagnoses, estimation of risk of malignancy by experienced ultrasound examiners who used pattern recognition, and rate of correct diagnoses with regard to malignancy when using pattern recognition in women included and excluded in this analysis * confi dence interval) was used as the main indicator ( 34 ) . The index can take on any value between 0.5 and 1 and can be interpreted as the degree of overlap between two CA-125 distributions. A value of 1 means no overlap; i.e., patients from one group had higher CA-125 levels than any patient from the other group. A value of 0.5 means maximal overlap; i.e., CA-125 levels from patients in one group were not generally higher or lower than those in the other group. The index is mathematically identical to the area under the receiver operating characteristic curve, which may help nonstatisticians with the interpretation of , although a receiver operating characteristic curve analysis has different objectives ( 34 ) . We also report P values from the Mann -Whitney test. All statistical tests were two-sided.
Results
Patient Demographic and Tumor Characteristics
Of the 1066 patients in the IOTA database, 809 had CA-125 serum levels available and were included in this analysis. Table 1 gives an overview of the patients who were included and excluded from this study. Some centers did not measure serum CA-125 if the tumor was judged to be clearly benign on the basis of pattern recognition. Therefore, the group of excluded patients contained more young women, more premenopausal women, and more women with benign tumors than the group included in this study. Pattern recognition correctly classified 95% of the benign tumors in the patients included and in 96% of those excluded (difference = − 1%, 95% CI = − 4.1% to 2.4%, P = .583) and 88% versus 83% of the malignant tumors (difference = 5%; 95% CI = − 5.9% to 24.6%, P = .507).
CA-125 Levels and Histologic Diagnosis
Preoperative CA-125 serum levels differed depending on histology ( Fig. 1 ) . CA-125 serum levels were 30 U/mL or higher in 183 of the 242 women with malignancies (76%, 95% CI = 69.6% to 80.8%), 81 of the 128 with endometriomas (63%, 95% CI = 54.3% to 71.5%), 11 of the 19 with abscesses (58%, 95% CI = 34.0% to 78.9%), and 13 of the 29 with fibromas (45%, 95% CI = 27.0% to 64.0%). In contrast, CA-125 serum levels were 30 U/mL or higher in only nine of the 83 women with dermoid cysts (11%, 95% CI = 5.4% to 20.1%), 11 of the 84 with simple cysts (13%, 95% CI = 7.0% to 22.6%), and one of the 15 with hydrosalpinges (7%, 95% CI = 0.3% to 34.0%). The CA-125 serum levels in women with endometriomas, fibromas, or abscesses were similar to those in women with borderline ovarian malignancies. CA-125 serum levels were higher in women with stage I primary invasive ovarian cancers, rare malignancies, or metastases than in women with benign or borderline tumors. CA-125 levels were highest in women with stage II -IV primary invasive ovarian cancers. CA-125 serum levels were lower in women with stage I primary invasive ovarian cancers than in those with stage II ( = 0.75, 95% CI = 0.55 to 0.88, P = .017), stage III ( = 0.80, 95% CI = 0.69 to 0.87, P <.001), or stage IV ( = 0.87, 95% CI = 0.71 to 0.95, P <.001) cancers.
Pattern Recognition and Histologic Diagnosis
By use of pattern recognition, ultrasound examiners assigned a correct specific diagnosis to at least 80% of endometriomas (80%, 95% CI = 72.3% to 86.7%), dermoid cysts (84%, 95% CI = 74.3% to 91.1%), hydrosalpinges (93%, 95% CI = 66.0% to 99.7%), and primary invasive ovarian cancers (80%, 95% CI = 71.3% to 86.0%) ( Table 2 ). The examiners assigned a correct specific diagnosis to 333 (59%, 95% CI = 54.5% to 62.8%) of the 567 benign tumors. Among premenopausal women, 67% (95% CI = 62.3% to 72.2%) of the benign lesions and 48% (95% CI = 36.9% to 58.7%) of the malignant lesions were assigned a correct specific diagnosis. Among postmenopausal women, 44% (95% CI = 37.0% to 50.8%) of the benign lesions and 58% (95% CI = 49.5% to 65.5%) of the malignant lesions were assigned a correct specific diagnosis.
Comparison of Diagnostic Abilities Between Pattern Recognition and CA-125 Serum Levels
Pattern recognition correctly classified 93% (95% CI = 90.9% to 94.6%) of the tumors as benign or malignant, whereas a CA-125 serum cutoff value of 30 U/mL classified 72% (95% CI = 69.2% to 75.5%) of the tumors correctly ( Table 2 ) . By the use of CA-125 serum levels, at best 83% (95% CI = 80.3% to 85.6%) of the tumors were correctly classified with a cutoff value of 100 U/mL. However, when a CA-125 serum cutoff of 100 U/mL, instead of 30 U/mL, was used, CA-125 correctly classified as many as 94% (95% CI = 91.8% to 95.9%) of the benign tumors as benign but only 57% (95% CI = 50.5% to 63.3%) of the malignant tumors as malignant. Pattern recognition was superior to serum CA-125 (with a cutoff value of 30 U/mL) for correctly classifying both benign and malignant tumors (95% of benign tumors correctly classifi ed versus 71%: difference = 24%, 95% CI = 19.7% to 27.9%, P <.001; 88% of malignant tumors correctly classifi ed versus 76%: difference = 12%, 95% CI = 7.2% to 18.5%, P <.001). Pattern recognition remained superior after stratifying for menopausal status -98% of benign tumors in premenopausal women being correctly classifi ed by pattern recognition versus 67% by serum CA-125 (difference = 31%, 95% CI = 26.1% to 36.4%, P <.001), 81% of malignant tumors in premenopausal women being correctly classifi ed by pattern recognition versus 66% by CA-125 (difference = 15%, 95% CI = 3.3% to 26.5%, P = .012), 90% of benign tumors in postmenopausal women being correctly classifi ed by pattern recognition versus 79% by CA-125 (difference = 11%, 95% CI = 4.5% to 17.6%, P = .001), and 92% of malignant tumors in postmenopausal women being correctly classifi ed by pattern recognition versus 81% by CA-125 (difference = 11%, 95% CI = 5.6% to 18.0%, P <.001).
For each specifi c histologic diagnosis, pattern recognition was superior to serum CA-125. Pattern recognition correctly classifi ed most benign tumors associated with high levels of serum CA-125 as benign (i.e., endometriomas, fi bromas, and abscesses), and it correctly classifi ed more borderline tumors as malignant than did serum CA-125 at any cutoff value ( Table 2 ). For example, pattern recognition correctly classifi ed 86% (95% CI = 81.1% to 90.4%) of these four histologies, but a CA-125 cutoff of 30 U/mL correctly classifi ed only 41% (95% CI = 34.4% to 47.5%). Moreover, pattern recognition was superior to serum CA-125 for discriminating between benign tumors and borderline tumors ( Table 3 ) and between benign tumors and stage I primary invasive malignancies ( Table 4 ) in both pre-and postmenopausal women, irrespective of the CA-125 cutoff chosen to indicate malignancy.
CA-125 Levels in Premenopausal and Postmenopausal Women
To investigate the effect of menopause, we determined CA-125 serum levels in pre-and postmenopausal patients with regard to histology of adnexal masses. Among patients with benign masses, CA-125 serum levels were lower in postmenopausal women than in premenopausal women ( Fig. 2 ; median = 15 U/mL and 19 U/mL, respectively; = 0.61, 95% CI for = 0.56 to 0.66, P <.001). Among patients with malignant masses, CA-125 serum levels were higher for postmenopausal women than for premenopausal women (244.5 U/mL and 62.5, respectively; = 0.66, 95% CI for = 0.58 to 0.72, Table 2 . Rate of correct diagnoses in histologic subgroups, when using ultrasound findings (pattern recognition) versus when using CA-125, and rate of correct specific ultrasound diagnoses, when using pattern recognition
Histologic diagnosis
No. (27) 32 (62) 22 (42) 17 (33) 13 (25) 7 (13) 5 (10) 2 (4) Metastatic 38 76 10 (26) 35 (92) 30 (79) 20 (53) 18 (47) 14 (37) 9 (24) P <.001). Accordingly, the value for serum CA-125 when comparing benign and malignant masses was 0.73 (95% CI for = 0.67 to 0.78) in premenopausal patients and 0.89 (95% CI for = 0.85 to 0.92) in postmenopausal patients. Values overlapped substantially between pre-and postmenopausal women with the same histopathologic diagnosis, but for many benign diagnoses, the values tended to be lower in postmenopausal women than in premenopausal women, whereas they tended to be higher for abscesses and malignant diagnoses in postmenopausal women than in premenopausal women ( Fig. 3 ) . We observed that, among premenopausal patients, 52% (95% CI = 31.1% to 72.6%) of borderline tumors were mucinous and, among postmenopausal patients, 40% (95% CI = 21.8% to 61.1%) of borderline tumors were mucinous. Consequently, differences in CA-125 between pre-and postmenopausal patients may be explained by differences in the mixture of tumor types and possibly by differences in expression of CA-125 between these groups of patients ( Fig. 3 ) .
Median
Discussion
We found that pattern recognition by an experienced examiner was superior to assessing the level of serum CA-125 for discrimination between benign and malignant adnexal masses. We also elucidated the distribution of CA-125 serum levels among patients with various types of adnexal masses and investigated the potential utility of serum CA-125 in the preoperative characterization of these tumors. Other publications have described increased levels of serum CA-125 in patients with malignant tumors ( 9 , 13 , 35 , 36 ) and described an association between CA-125 serum levels and the stage and histology of tumors. We have also confirmed that women with ovarian carcinoma, primarily late stage disease, have increased levels of serum CA-125 ( 9 , 13 , 36 , 37 ) and that women with borderline and stage I tumors, which are more difficult to detect clinically and to diagnose correctly as malignant than advanced stage cancers, have a relatively low level of serum CA-125 ( 38 -40 ) . Patients with mucinous cancers have elevated CA-125 serum levels less often than patients with serous and undifferentiated epithelial cancers ( 37 ) . Patients with other primary cancers, such as those of the endometrium, pancreas, liver, or lung, may also have elevated levels of serum CA-125 ( 9 , 13 ) .
Few published studies have focused on CA-125 serum levels in women with benign adnexal tumors. However, it has been reported that the level of serum CA-125 is often elevated in women with endometriosis or endometriomas ( 6 , 9 , 13 , 38 , 41 -43 ) . For example, Jacobs and Bast ( 13 ) found that CA-125 serum levels exceeded 35 U/mL in approximately 10% of women with benign tumors and in a higher percentage of women with serous benign tumors than among those with cystic teratomas. Our results agree with those of others in that CA-125 serum levels were elevated more often among premenopausal women with benign tumors than among postmenopausal women with benign tumors ( 9 , 41 ) and thus were more useful in distinguishing between benign and malignant tumors in postmenopausal patients ( 36 , 44 , 45 ) . These different results between pre-and postmenopausal patients could be explained by the different mixtures of tumor types in pre-and postmenopausal patients -34% of all benign masses among premenopausal women were endometriomas (which are associated with increased levels of serum CA-125), compared with only 2% among postmenopausal women, and 50% of all malignant masses among postmenopausal women were primary invasive cancers of stage II -IV (which are associated with very high levels of serum Table 3 . Diagnostic performance of subjective evaluation of the ultrasound image by the ultrasound examiner (pattern recognition) and of serum CA-125 level in a population of women with benign tumors or borderline tumors *
Population
Diagnostic method % Acc (95% CI) % Sens (95% CI) % Spec (95% CI) LR+ (95% CI) LR - (95% CI) CA-125), compared with only 31% of malignant masses among premenopausal women. Surprisingly, however, there were also some differences in CA-125 serum levels between pre-and postmenopausal women with the same histologic diagnosis. Compared with premenopausal women with similar tumor types, postmenopausal women with various benign tumor types tended to have lower CA-125 serum levels, whereas postmenopausal women with malignant tumors had higher CA-125 serum levels, irrespective of tumor type and stage. These observations might be explained by differential tumor behaviors in pre-and postmenopausal women with the same tumor types and differences in type of borderline tumors in these groups of women (i.e., borderline tumors tended to be mucinous more often in premenopausal women than in postmenopausal women), in tumor size, or in the spread of malignant tumors of the same stage. We have shown that 752 (93%) of the 809 tumors were correctly classifi ed as malignant or benign by pattern recognition, and in 464 (57%) of these tumors, a correct specifi c histologic diagnosis was proposed. At any serum CA-125 cutoff level used, serum CA-125 resulted in more misclassifi cations with regard to malignancy than pattern recognition. Our fi ndings are in line with those in our previous report from the IOTA study ( 46 ) , in which serum CA-125 was not retained as a variable in a logistic regression model that was designed to discriminate between benign and malignant adnexal masses. Other studies ( 23 -26 ) have also shown that experienced ultrasound examiners can generally make a correct diagnosis with regard to the nature of a mass by the subjective evaluation of gray-scale and Doppler ultrasound fi ndings, i.e., pattern recognition. These fi ndings are clinically relevant for patients with an ovarian mass because clinicians often use the CA-125 serum level in such patients to estimate the likelihood that the mass is malignant. As a result of this analysis, we suggest that this approach may not be as helpful as pattern recognition.
This study has several limitations. One is that CA-125 serum levels were not available for 24% of case patients in the original IOTA study population. An analysis of the masses without information on serum CA-125 ( Table 1 ) showed that most masses were benign and were classifi ed correctly as benign with a high level of confi dence by use of pattern recognition. This fi nding reveals a bias to the study whereby serum CA-125 is more likely to have been measured in women with lesions that were suspected of being malignant by the ultrasound examination than in women with lesions that were suspected of being benign. We do not believe that this bias invalidates our conclusions, because in all likelihood, serum CA-125 would have performed more poorly in the patients excluded in this study than in the included patients, given the large proportion of endometriomas and the small proportion of stage III and IV cancers in the excluded group. Another limitation is that fi ve CA-125 kits were used to assess the level of serum CA-125. The use of multiple kits may have introduced more variation in the CA-125 results than if only a single kit had been used. However, this procedure refl ects clinical reality, and previous studies have found that variation in the results from the different kits is not large ( 47 , 48 ) . In light of our results, it is diffi cult to understand why measurement of CA-125 serum levels is such an entrenched part of the preoperative evaluation of adnexal masses. It probably refl ects a lack of confi dence in the use of ultrasonography despite numerous reports in the literature that transvaginal ultrasound can be used to classify most ovarian masses with a high degree of accuracy ( 23 -25 ) . The accuracy, however, depends on the level of experience of the examiner; little variation in accuracy has been found between experienced examiners ( 23 ) . Our results were obtained by specialized gynecologic ultrasound units. The quality of ultrasound outside such centers is almost certainly more variable. We hope our results will encourage responsible parties to expend more effort and more resources to educate and train those who perform gynecologic ultrasound examinations, so that the potential of the ultrasound technique can be maximized. 
